First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.

MLA

Lee, Ki Hyeong, et al. “First-Line Nivolumab plus Platinum Chemotherapy and Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer: A 3-Year Follow-up of the Phase 3 Randomized TASUKI-52 Trial.” Lung Cancer (Amsterdam, Netherlands), vol. 201, Mar. 2025, p. 108109. EBSCOhost, https://doi.org/10.1016/j.lungcan.2025.108109.

APA

Lee, K. H., Lee, J.-S., Sugawara, S., Kang, J. H., Kim, H. R., Inui, N., Hida, T., Yoshida, T., Tanaka, H., Yang, C.-T., Inoue, T., Nishio, M., Ohe, Y., Tamura, T., Yamamoto, N., Yu, C.-J., Akamatsu, H., Takahashi, S., & Nakagawa, K. (2025). First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial. Lung Cancer (Amsterdam, Netherlands), 201, 108109. https://doi.org/10.1016/j.lungcan.2025.108109

Chicago

Lee, Ki Hyeong, Jong-Seok Lee, Shunichi Sugawara, Jin Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, et al. 2025. “First-Line Nivolumab plus Platinum Chemotherapy and Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer: A 3-Year Follow-up of the Phase 3 Randomized TASUKI-52 Trial.” Lung Cancer (Amsterdam, Netherlands) 201 (March): 108109. doi:10.1016/j.lungcan.2025.108109.